Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Lucknow, India.
KBI Biopharma, Analytical and Formulation Sciences, Geneva, Switzerland.
Expert Opin Biol Ther. 2023 Jul-Dec;23(7):603-618. doi: 10.1080/14712598.2023.2227378. Epub 2023 Jun 27.
Recombinant monoclonal antibodies (mAbs) are highly selective and effective biologicals with proven utility as therapeutics. mAbs have demonstrated substantial promise in the treatment of several central nervous system diseases.
Databases including PubMed and Clinicaltrials.gov were used to identify clinical studies of mAbs involving patients with neurological disorders. This manuscript reviews the current status and recent advances in the development and engineering of therapeutic blood-brain barrier (BBB)-crossing mAbs and their potential in treatment of central nervous system diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), brain tumors, and neuromyelitis optica spectrum disorder (NMSOD). In addition, the clinical implications of recently developed monoclonal antibodies are also discussed, along with the strategies to enhance their BBB permeability. The adverse events associated with the administration of monoclonal antibodies are also presented in the manuscript.
There is growing evidence that supports the therapeutic utility of monoclonal antibodies in central nervous system and neurodegenerative diseases. Several studies have offered evidence of clinical efficacy in AD through use of anti-amyloid beta antibodies and anti-tau passive immunotherapy-based strategies. Additionally, ongoing research trials have produced promising findings for the treatment of brain tumors and NMSOD.
重组单克隆抗体（mAbs）是高度选择性和有效的生物制剂，已被证明可作为治疗药物使用。mAbs 在治疗几种中枢神经系统疾病方面显示出巨大的应用潜力。
使用 PubMed 和 Clinicaltrials.gov 等数据库，确定了涉及神经障碍患者的 mAbs 临床研究。本文综述了治疗性血脑屏障（BBB）穿透 mAbs 的开发和工程的现状和最新进展，及其在治疗中枢神经系统疾病（如阿尔茨海默病（AD）、帕金森病（PD）、脑肿瘤和视神经脊髓炎谱系障碍（NMSOD））中的潜在应用。此外，还讨论了最近开发的单克隆抗体的临床意义，以及增强其 BBB 通透性的策略。本文还介绍了与单克隆抗体给药相关的不良反应。
越来越多的证据支持单克隆抗体在中枢神经系统和神经退行性疾病中的治疗效用。一些研究通过使用抗淀粉样蛋白β抗体和基于抗 tau 的被动免疫疗法策略，提供了 AD 临床疗效的证据。此外，正在进行的研究试验为脑肿瘤和 NMSOD 的治疗提供了有希望的结果。
